Document is current
Any future updates will be listed below
-
Authors
Zhao, Yue http://orcid.org/0000-0003-3645-2634
Gao, Jian http://orcid.org/0000-0002-0446-7471
Wang, Jun http://orcid.org/0009-0005-4877-0930
Fan, Fanfan
Cheng, Chao
Qian, Danwen http://orcid.org/0000-0002-6209-0764
Guo, Ran
Zhang, Yang
Ye, Ting
Augustine, Marcellus
Lin, Yicong
Shang, Jun http://orcid.org/0000-0002-5767-1492
Li, Hang
Pan, Yunjian
Huang, Qingyuan
Chen, Haiqing
Han, Han
Gao, Zhendong
Wang, Qiming
Zhang, Shiyue
Zhang, Mou
Fu, Fangqiu
Yan, Yueren
Fernandez Patel, Shanila
Vendramin, Roberto http://orcid.org/0000-0001-7191-4887
Yuan, Hui
Zhang, Yawei
Xiang, Jiaqing
Hu, Hong
Sun, Yihua http://orcid.org/0000-0002-5287-0601
Li, Yuan http://orcid.org/0000-0001-9338-2463
Litchfield, Kevin http://orcid.org/0000-0002-3725-0914
Cao, Zhiwei http://orcid.org/0000-0003-1165-1928
Chen, Haiquan http://orcid.org/0000-0001-7846-257X
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (81930073, 82203037)
- License Information
-
More Information
Article History
Received: 12 September 2023
Accepted: 28 August 2024
First Online: 10 September 2024
Competing interests
: The authors declare the following competing interests: K.L. has the following disclosures (all outside of the submitted work): patent on indel burden and CPI response pending, patent on ctDNA minimal residual disease calling methods; speaker fees from Roche tissue diagnostics and Ellipses pharma; research funding from CRUK TDL/Ono/LifeArc alliance and Genesis Therapeutics; and consulting roles with Monopteros Therapeutics, Kynos Therapeutics and Tempus Labs, Inc. M.A. is supported by the City of London Centre Clinical Academic Training Programme (Year 3, SEBSTF-2021\100007). All the other authors declare no competing interests.
